Spectrum of Seasonal Allergic Rhinitis Symptom Relief with Topical Corticoid and Oral Antihistamine Given Singly or in Combination

Carter D. Brooks, M.D., Steven F. Francom, Ph.D., Bruce G. Peel, B.S., Brenda L. Chene, R.N., and Karen A. Klatt, R.N.

ABSTRACT

Sixty ragweed-sensitive volunteers participated in a 2-week study that compared symptom profiles during treatment with antihistamine (loratadine, LOR) alone, topical corticoid (beclomethasone, BEC) alone, or the two drugs combined. For 5 days commencing shortly after the beginning of the ragweed bloom, patients took no treatment while we collected baseline data. They were then randomized to one of the three treatments, receiving that treatment for the balance of the 2-week study term. Twice each day they recorded the severity of congestion, eye symptoms, running and blowing, itching, and sneezing. At the end of the study they provided an estimate of overall symptom relief, which favored combined treatment (vs LOR P = 0.001, vs BEC P = 0.042). To gain an estimate of disease severity and treatment effectiveness over time, and to smooth out day-to-day variation, we divided symptom diary reports into three segments (days 2-4, 5-7, and 8-10) for analysis. Combined treatment controlled symptoms better than antihistamine alone in nearly all study segments. Corticoid alone or combined with antihistamine provided similar control of congestion, running and blowing, and eye complaints. Combination therapy controlled itching and sneezing better, especially through the study segments 1 and 2. Patient preference for combined treatment seems to relate to control of itching and sneezing and rapid onset of effect. (American Journal of Rhinology 10, 193-199, 1996)

In several previous studies we have examined profiles of individual symptoms in allergic rhinitis and the selective effects of various treatments on these profiles. We showed that, compared to placebo, terfenadine suppressed sneeze, itch, and eye symptoms, benefitted congestion marginally, and failed to improve running and blowing. Of these, only control of sneezing appeared quickly after introduction of the drug in midseason.1 Another study intended to establish minimal effective doses of oral methylprednisolone found, at 6 mg per day, significant suppression of congestion, postnasal drainage, and eye symptoms, but not itching, sneezing, and running.2 These findings could be a clinical expression of the reported inability of systemic corticoid to prevent release of mediators from human mast cells.3

It appeared that the symptoms most responsive to antihistamine treatment responded least well to low dose corticoid and vice versa, providing a rational basis for combination of the two drug types for seasonal allergic rhinitis
treatment. We have carried out preliminary studies documenting additive protection with combined antihistamine/corticoid treatment, and the equivalence of oral and topical corticoid when given as part of the combination.

Others have studied symptom control with combined antihistamine/topical corticoid treatment and have reported variable findings. Most reported a more modest increment of patient-perceived benefit with combined treatment than our preliminary studies led us to expect.

The goal of the study reported here was to compare profile and severity of individual symptoms, and overall patient perception of benefit during seasonal allergic rhinitis treatment with antihistamine (loratadine, Claritin, Schering-Plough, LOR) alone, topical nasal corticoid (beclomethasone, Vancenase AQ, Schering-Plough, BEC) alone, and the two drugs in combination. The study did not contain a concurrent placebo control group, but all study participants entered the treatment comparison from an untreated baseline observation period.

STUDY DESIGN AND EXECUTION

Subject Selection

Sixty subjects enrolled in and completed the study. Each treatment group contained 20 people; sex distribution in the LOR group was 10M/10F, whereas the BEC and the LOR/BEC groups both had 7M/13F. The three treatment groups were roughly comparable in age, height, and weight. All had reliable histories of seasonal rhinitis compatible with ragweed seasonal allergic rhinitis and strongly positive ragweed skin (prick) tests. Many had participated in previous studies and had provided records of the severity of their seasonal symptoms. None had evidence of significant complicating disease on history, physical examination, or screening laboratory testing; women had negative pregnancy tests on entry and again in mid-study. All alleged that they understood the design, demands, and risks of the study and signed their consent to participate. The Bronson Hospital Human Use Committee reviewed and approved the study design and documents.

Treatment Schedule

In this community, ragweed typically begins to bloom around August 15. Subjects came under study observation on 18 August (Thursday) and were seen each Monday and Thursday through 1 September. From August 18 to 22 they used no treatment; this provided baseline information documenting seasonal allergic rhinitis severity at the beginning of the observation period. After 22 August they used their randomly assigned therapy, remaining on the same treatment through 1 September. At all visits we reviewed and verified hay fever symptom severity diaries, checked apparent study drug consumption, and inquired for possible treatment side effects or other medical events.

Table I shows the pollen counts obtained during the study confirming the appearance of reasonable levels by mid-August. (James L. McDonald, M.D., provided aeroallergen counts obtained from a rotobar sampler located at an elevated urban site about one mile from the clinic where we ran the study.) Absolute counts never exceeded 169 grains per cubic meter, relatively low compared with prior years’ experiences. However, they seemed to provide an adequate allergic stimulus, both in study subjects and nonstudy patients under our care.

Experimental Drug Treatment

We randomly allocated volunteers to three drug treatment groups consisting of:

1. Loratadine (Claritin, Schering-Plough) (LOR) 10 mg once a day, plus a placebo spray twice a day.
2. Beclomethasone (Vancenase AQ, Schering-Plough) (BEC) two sprays (about 84 mcg) each side of the nose twice a day, plus placebo LOR.
3. BEC twice a day plus LOR once daily.

During the treatment comparison, subjects took no other treatment that might affect their hay fever.

<table>
<thead>
<tr>
<th>Study Segment</th>
<th>Date</th>
<th>Ragweed Count</th>
<th>Study Segment</th>
<th>Date</th>
<th>Ragweed Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>August 19</td>
<td>27</td>
<td>Baseline</td>
<td>August 20</td>
<td>14</td>
</tr>
<tr>
<td>Baseline</td>
<td>August 21</td>
<td>59</td>
<td>Baseline</td>
<td>August 22</td>
<td>23</td>
</tr>
<tr>
<td>Baseline</td>
<td>August 23</td>
<td>83</td>
<td>Baseline</td>
<td>August 24</td>
<td>162</td>
</tr>
<tr>
<td>Baseline</td>
<td>August 25</td>
<td>169</td>
<td>Baseline</td>
<td>August 26</td>
<td>95</td>
</tr>
<tr>
<td>Baseline</td>
<td>August 27</td>
<td>144</td>
<td>Baseline</td>
<td>August 28</td>
<td>144</td>
</tr>
<tr>
<td>Baseline</td>
<td>August 29</td>
<td>116</td>
<td>Baseline</td>
<td>August 30</td>
<td>76</td>
</tr>
<tr>
<td>Baseline</td>
<td>August 31</td>
<td>67</td>
<td>Baseline</td>
<td>September 1</td>
<td>45</td>
</tr>
<tr>
<td>Baseline</td>
<td>September 2</td>
<td>19</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ragweed Pollen Grain Count in Particles Per CU Meter. Counts Made Using A Rotobar Sampler Running Intermittently on a Downtown Rooftop.
Symptom Severity Diaries recorded the level of discomfort perceived by the subjects for each of five classes of seasonal allergic rhinitis symptoms. The diary has served us well in earlier studies.

All subjects made twice daily entries for the following hay fever-related problems:

- Congestion
- Running and blowing
- Sneezing
- Itching
- Eye symptoms

For each symptom the diary contained a scale specifically describing five levels of severity. The diary also provided space for recording use of study drug, need for any intercurrent medications, possible adverse reactions to the study drugs, and amount of time spent in air-conditioning.

Global Assessment

On the final treatment day, we asked all subjects to rate their response to treatment as excellent, good, fair, or poor. Although crude and subjective, this approach has clearly differentiated among treatments in past studies.

DATA HANDLING AND STATISTICAL ANALYSIS

We omitted symptom severity scores from the first and last days, as these typically included half day reports only, as well as the first full treatment day, feeling that it still reflected a transition day providing questionable data. To allow comparison with baseline and perception of developing trends, we collapsed symptom severity reports into four intervals; days -3 to -1 (pretreatment), and treatment days 2–4, 5–7, and 8–10. We averaged AM and PM scores and calculated change from mean pretreatment score for each subject and each follow-up day. Each symptom change score was analyzed using a repeated measures analysis of variance model incorporating factors associated with treatment, subject nested within treatment, study day, and treatment by day interaction. In addition, the mean pretreatment response was used as a covariate. We used contrast statements to make treatment comparisons within each of the 3-day follow-up periods. A pooled error term containing both the within- and between-subject errors was used in testing. All analyses were done using SAS (SAS Institute, Cary, NC).

RESULTS

Symptom Severity During Baseline

Table II contains overall mean symptom severity scores collected during the baseline period. During this interval, the volunteers took no medications to suppress their rhinoconjunctivitis. Diaries allowed description of symptoms on a discrete scale from 1 (no symptoms) to 5 (maximum symptoms). Baseline values largely between 2 and 3 suggest that patients experienced mild to moderate symptoms during this time and that symptom severity was reasonably homogeneous across the three groups.

Overall Patient Assessment

At the last clinic visit, on the last day of study-imposed therapy, we asked each subject for an overall estimate of the effectiveness of the treatment they had just completed. Their options were excellent, good, fair, or poor; we did not qualify these further.

Table III contains results of the patient ratings. Combination treatment provided superior symptom control with 19/20 reporting good (8) or excellent (11) results. The combination was significantly superior to topical steroid alone \((P = 0.042)\), and to antihistamine alone \((P = 0.001)\). BEC alone appeared to protect slightly better than LOR alone, but statistical testing did not confirm the significance of this trend \((P = 0.122)\).

Diary Symptom Severity Scores

Figures 1 through 5 show mean changes in symptom severity from pretreatment to the indicated treatment segment. We looked for treatment effect by determining symptom severity decrements from baseline and testing these for significance using the paired \(t\)-test.

The figures show several patterns. Antihistamine alone (LOR, L) produced relatively modest benefit, almost always less than that seen with either of the topical corticoid-
containing regimens. Antihistamine benefitted congestion (Fig. 1) slightly in segments 1 and 2, and not at all in segment 3. Eye symptoms (Fig. 2) improved minimally though never significantly, while running and blowing (Fig. 3) showed no LOR-induced improvement. Itching (Fig. 4) showed consistent and significant lessening during LOR treatment, whereas sneezing (Fig. 5) improved in segments 1 and 2, but not 3.

Comparing among the treatments, three diary entries, congestion, eye symptoms, and running/blowing showed
similar improvement with BEC and BEC/LOR combined treatment. Combined treatment benefited sneezing and itching significantly better than BEC alone (see Table IV) in most of the treatment segments. With BEC alone suppression of sneezing increased gradually from Segments 1 through 3, though the difference from baseline was significant in all segments. With combined BEC/LOR sneeze suppression appeared promptly and already was maximum in Segment 1; by Segment 3, BEC and BEC/LOR provided similar suppression of sneezing (albeit
Figure 5. Sneezing Mean Change by Treatment Group and Study Segment. Group and Segment as in Figure 1.

Table IV

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Segments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Congestion</td>
<td>0.4461</td>
</tr>
<tr>
<td>Eye symptoms</td>
<td>0.0474</td>
</tr>
<tr>
<td>Running/blowing</td>
<td>0.0923</td>
</tr>
<tr>
<td>Itching</td>
<td>0.0532</td>
</tr>
<tr>
<td>Sneezing</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

DISCUSSION

In analyzing studies of seasonal allergic rhinitis treatment, we have compared symptom responses day by day, or alternatively looked at an integrated response over the entire study. Both approaches have presented problems. Looking at days individually produces a great deal of variation and more data than is really necessary to compare effectiveness of several treatments. It will allow insight into developing trends and is necessary if one wishes to correlate symptom severity with something peculiar to that day, such as weather conditions. A single integrated symptom severity score representing the typical experience of subjects on a given treatment may suffice to compare treatments, but it cannot sense differences in the profile of development of symptom control over time. Trying to benefit from the strengths of each of these approaches, we divided this study into 3-day segments, which provided satisfactory indication of temporal patterns while smoothing out day-to-day variation.

We had originally noted that low dose corticoid primarily benefitted congestion, drainage, and eye symptoms, whereas antihistamine affected primarily itching and sneezing. This led us to postulate that combination of these drug types would benefit more symptoms but not provide improved control of individual parts of the syndrome. In fact, our results suggest additive symptom suppression almost across the board. With itching and sneezing, which showed the greatest increment of benefit from combination treatment, the data suggest that both drugs contributed some

still testing statistically different at a 0.0589 level). With itching, BEC/LOR provided significantly greater suppression than BEC alone in all segments. Unlike sneezing, control of itching with BEC alone did not increase progressively nor approach that achieved with combination treatment. The difference in itching intensity between LOR and LOR/BEC, although suggestive in segment 1, tested less than significant \( P = 0.1298 \). With segments 2 and 3, and every other symptom, combined therapy performed highly significantly better than antihistamine alone \( P < 0.001 \).
symptom control and the improvement seen with the combination resulted from addition of the effects of the component drugs. This suggests other possible avenues of inquiry: what different drug mechanisms affect a given symptom; what about dose-response relationships with the component drugs?

We have examined both single drugs and the combination in an acute nasal allergen challenge model, looking only at clinical endpoints. For sneezing and secretion, combined treatment had no more effect than corticoid alone. However, allergen-induced rises in measured nasal airway resistance showed no protection from antihistamine alone, partial suppression with corticoid alone and total suppression with the combination. Adding antihistamine, which typically affects measured nasal resistance or perceived congestion very little, to topical steroid seemed to facilitate its antiobstructive effect in the acute challenge model, but seemed to affect that part of the real disease minimally.

Others have examined combination treatment and typically reported a modest increment of benefit with combined compared with single drug treatment. D’Souza found similar numbers of symptom-free days with nasal steroid or nasal steroid plus antihistamine. A retrospective patient judgement on success in controlling nasal symptoms yielded 76.6% for steroid alone and 85.5% for the steroid/antihistamine combination. There was a similar, modest increment for eye symptoms and headache. Backhouse et al. found a substantial increment of benefit in all symptoms examined comparing antihistamine alone to antihistamine plus nasal steroid. That study did not include a steroid-alone arm.

In a study of astemizole, beclomethasone, and the two drugs combined, Juniper et al. found that beclomethasone plus astemizole provided no better control of rhinitis than beclomethasone alone. Symptoms examined included sneezing, runny nose, stuffy nose, and eye complaints. They did find a significantly higher use of rescue medication for eye problems among those taking nasal steroid alone.

Simpson compared placebo, budesonide, terfenadine, and budesonide/terfenadine, looking at severity scores for nasal blockage, runny nose, nasal itching, and sneezing. Among these, only sneezing showed better control with the combination than with budesonide alone. Patients' overall assessment showed definite preference for the budesonide-containing regimens, but essentially no difference between corticoid alone and combined with terfenadine.

Splitting our patient responses into early, mid, and late segments allowed us to smooth out short-term variability and gauge therapeutic effects that take some time to develop. Symptoms that showed gradual onset of control with BEC alone included sneezing and possibly itching and eye symptoms (Figs. 5, 4, and 2 respectively). These same symptoms showed rapid development of maximum control with combined BEC/LOR treatment. Several articles have looked at the effect of topical corticoid treatment on nasal mucosal mast cell populations, and all have agreed that over a period of time such as we studied here, total mast cell numbers changed little. One group found decreased histamine content in the steroid-treated nasal mucosa without accompanying change in mast cell numbers. This suggested to them that the topical corticoid had decreased the mast cell histamine pool. Others found no changes in overall numbers but a corticoid-associated reduction in numbers of formalin-sensitive mast cells, indicating differential effects on mast cell subpopulations. Sneezing responds quickly to antihistamine treatment, and we have felt that it largely represents the effects of locally elaborated histamine. The pattern of control of sneezing seen in this study may reflect the gradual onset of corticoid influence on the local mast cell population in the BEC alone group, and this effect plus immediate histamine blockade in those getting both corticoid and antihistamine.

This study confirms the overall effectiveness of combined corticoid/antihistamine treatment for ragweed seasonal allergic rhinitis and shows that some symptoms remit better and sooner when combined treatment is applied. It has not afforded us any additional insight into possible reasons for this complementary effect. In contrast with earlier studies, our patients preferred combined treatment by a substantial margin, a finding that may correlate with quicker and overall better control of sneezing and itching. We believe that combined antihistamine-topical corticoid treatment will provide a very satisfactory level of comfort for most seasonal allergic rhinitis patients and should be the preferred treatment at this time.

REFERENCES


